Should We Look beyond Revised International Prognostic Scoring System: A Retrospective Observational Study of Progression of Myelodysplastic Syndrome to Acute Leukemia

Bangalore Rammohan Nagarjun; Rajashekar Kalaharaghini; Jyoti Sawhney; Pina J. Trivedi; Karthik Dhandapani; Biren Parikh

doi:10.1055/s-0041-1736175

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(05): 431-438
DOI: 10.1055/s-0041-1736175

Original Article

Should We Look beyond Revised International Prognostic Scoring System: A Retrospective Observational Study of Progression of Myelodysplastic Syndrome to Acute Leukemia

Bangalore Rammohan Nagarjun

¹Department of OncoPathology, The Gujarat Cancer & Research Institute, Ahmedabad, Gujarat, India

,

Rajashekar Kalaharaghini

¹Department of OncoPathology, The Gujarat Cancer & Research Institute, Ahmedabad, Gujarat, India

,

Jyoti Sawhney

¹Department of OncoPathology, The Gujarat Cancer & Research Institute, Ahmedabad, Gujarat, India

,

Pina J. Trivedi

¹Department of OncoPathology, The Gujarat Cancer & Research Institute, Ahmedabad, Gujarat, India

,

Karthik Dhandapani

¹Department of OncoPathology, The Gujarat Cancer & Research Institute, Ahmedabad, Gujarat, India

,

Biren Parikh

¹Department of OncoPathology, The Gujarat Cancer & Research Institute, Ahmedabad, Gujarat, India

› Author Affiliations

Abstract

Introduction Myelodysplastic syndrome (MDS) is a clonal stem cell disorder and heterogeneous condition resulting in peripheral cytopenias with marrow dysplasia due to ineffective hematopoiesis. The revised International Prognostic Scoring System (IPSS-R) predicts the risk of progression to acute leukemia (AL). Indian data on MDS and its progression to AL are limited. Additionally, the cytogenetic findings are dictated by patients' racial background. Study intended to analyze the cytogenetic profile of the patients with MDS.

Objectives This study aimed to (1) evaluate the clinicohematologic and morphologic spectrum of newly diagnosed MDS cases, (2) evaluate the cytogenetic profile of these cases, and (3) study the cases progressed to AL.

Materials and Methods MDS cases diagnosed and followed-up during a 5-year study period, from January 2015 to December 2019, were included in the study and the study was conducted at regional cancer center in Western India. De novo diagnosed MDS cases with complete workup were considered and MDS due to secondary causes were excluded. Baseline clinical, hematologic findings were tabulated along with cytogenetics and risk stratified as per IPSS-R, and their progression was studied.

Results A total of 63 cases of de novo MDS were diagnosed over a period of 5 years with 45 cases on follow-up and 15 cases (33.3%) progressed to AL. Maximum number of cases belonged to MDS-excess blast (EB) category accounting to 48 cases (76.1%). Apparently normal karyotyping was the commonest cytogenetic finding in 33 MDS cases (61.2%) and in 8 cases that progressed to AL (53.4%).

Conclusion MDS cases diagnosed at relatively early age were at higher risk of progression to AL. Majority of the cases that progressed to AL were risk stratified in high and very high risk groups and 10 cases which progressed to AL belonged to good category, interestingly apparent normal karyotyping was the commonest cytogenetic finding in more than 50% of the cases progressed to AL. Molecular mutations could only explain this progression and studies integrating molecular mutations with present IPSS-R scoring system should be conducted, as it could translate into better risk stratification and help in early identification and better management of cases at risk in progression to AL.

Keywords

myelodysplastic syndrome - acute leukemia - International prognostic scoring system - cytogenetics

Full Text

References

References
1 Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009; 361 (19) 1872-1885
2 Devita Jr. VT, Lawrence TA, Rosenberg SA. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 9th ed.. Philadelphia, PA: Wolters Kluwer; 2011
3 Visconte V, Selleri C, Maciejewski JP, Tiu RV. Molecular pathogenesis of myelodysplastic syndromes. Transl Med UniSa 2014; 8 (04) 19-30
4 Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 2006; 81 (01) 104-130
5 Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol 2008; 87 (07) 515-526
6 Shukron O, Vainstein V, Kündgen A, Germing U, Agur Z. Analyzing transformation of myelodysplastic syndrome to secondary acute myeloid leukemia using a large patient database. Am J Hematol 2012; 87 (09) 853-860
7 Swerdlow SH, Campo E, Harris NL. et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th ed.. Lyon, France: IARC; 2017
8 Swoboda DM, Sallman DA. Mutation-driven therapy in MDS. Curr Hematol Malig Rep 2019; 14 (06) 550-560
9 Walter MJ, Shen D, Ding L. et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012; 366 (12) 1090-1098
10 Bejar R, Stevenson K, Abdel-Wahab O. et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364 (26) 2496-2506
11 Georgiou G, Karali V, Zouvelou C. et al. Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance. Br J Haematol 2006; 134 (03) 302-306
12 Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000; 96 (12) 3932-3938
13 Watanabe-Okochi N, Kitaura J, Ono R. et al. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood 2008; 111 (08) 4297-4308
14 Lindsley RC, Mar BG, Mazzola E. et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 2015; 125 (09) 1367-1376
15 Makishima H, Yoshizato T, Yoshida K. et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet 2017; 49 (02) 204-212
16 Ogawa S. Genetics of MDS. Blood 2019; 133 (10) 1049-1059
17 McGowan-Jordan J, Simons A, Schmid M. International Standing Committee on Human Cytogenomic Nomenclature. ISCN: An International System for Human Cytogenetic Nomenclature (2016). Basel, New York: Karger; 2016: 14
18 Chaubey R, Sazawal S, Mahapatra M, Chhikara S, Saxena R. Does Indian myelodysplastic syndrome have a biology different from that in the West?. Asian Pac J Cancer Prev 2016; 17 (04) 2341-2342
19 Lee JJ, Kim HJ, Chung IJ. et al. Comparisons of prognostic scoring systems for myelodysplastic syndromes: a Korean multicenter study. Leuk Res 1999; 23 (05) 425-432
20 Chen B, Zhao WL, Jin J. et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia 2005; 19 (05) 767-775
21 Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007; 109 (08) 1536-1542
22 Neukirchen J, Schoonen WM, Strupp C. et al. Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. Leuk Res 2011; 35 (12) 1591-1596
23 Algarni AA, Akhtari M, Fu K. Myelodysplastic syndrome with myelofibrosis transformed to a precursor B-cell acute lymphoblastic leukemia: a case report with review of the literature. Case Rep Hematol 2012; 2012: 207537
24 Jiang Y, Eveillard JR, Couturier MA. et al. Asian population is more prone to develop high-risk myelodysplastic syndrome, concordantly with their propensity to exhibit high-risk cytogenetic aberrations. Cancers (Basel) 2021; 13 (03) 481
25 Chaubey R, Sazawal S, Dada R, Mahapatra M, Saxena R. Cytogenetic profile of Indian patients with de novo myelodysplastic syndromes. Indian J Med Res 2011; 134 (04) 452-457
26 Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS, Maciejewski JP. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008; 111 (03) 1534-1542
27 Haase D, Germing U, Schanz J. et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007; 110 (13) 4385-4395
28 Kawata E, Xenocostas A, Hsia CC. et al. Reevaluating the role of cytogenetic testing in patients with suspected myelodysplastic syndrome in the era of next generation sequencing. Blood 2019; 134 (Suppl. 01) 3438
29 Menssen AJ, Walter MJ. Genetics of progression from MDS to secondary leukemia. Blood 2020; 136 (01) 50-60
30 National Comprehensive Cancer Network. Myelodysplastic syndrome (version 2.2020). Accessed August 10, 2021 at: http://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
31 Haase D, Stevenson KE, Neuberg D. et al; International Working Group for MDS Molecular Prognostic Committee. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia 2019; 33 (07) 1747-1758
32 Sanz GF, Ibañez M, Such E. Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?. Blood Adv 2019; 3 (21) 3454-3460
33 Pagliuca S, Gurnari C, Visconte V. Molecular targeted therapy in myelodysplastic syndromes: new options for tailored treatments. Cancers (Basel) 2021; 13 (04) 784
34 Roy S, Coldren C, Karunamurthy A. et al. Standards and guidelines for validating next-generation sequencing bioinformatics pipelines: a joint recommendation of the Association for Molecular Pathology and the College of American Pathologists. J Mol Diagn 2018; 20 (01) 4-27
35 Palomo L, Ibáñez M, Abáigar M. et al; Spanish Group of MDS (GESMD). Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2020; 188 (05) 605-622
36 Du MY, Xu M, Deng J. et al. Evaluation of different scoring systems and gene mutations for the prognosis of myelodysplastic syndrome (MDS) in Chinese population. J Cancer 2020; 11 (02) 508-519
37 Platzbecker U. UwePlatzbecker. Treatment of MDS. Blood 2019; 133 (10) 1096-1107

Supplementary Material

Supplementary Material